Clinical status and optimal use of the cardioprotectant, dexrazoxane.
Blum
R H
RH
New York Medical College Valhalla, New York, USA.
D000903:Antibiotics, Antineoplastic / Q000009:adverse effects / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000378:metabolism / Q000532:radiotherapy; D002317:Cardiovascular Agents / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D003131:Combined Modality Therapy; D004305:Dose-Response Relationship, Drug; D004317:Doxorubicin / Q000009:adverse effects / Q000627:therapeutic use; D005260:Female; D006321:Heart / Q000187:drug effects* / Q000528:radiation effects; D006331:Heart Diseases / Q000139:chemically induced / Q000517:prevention & control*; D006801:Humans; D007501:Iron / Q000378:metabolism; D009206:Myocardium / Q000378:metabolism; D011929:Razoxane / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D012449:Safety; D016896:Treatment Outcome
D000903:Antibiotics, Antineoplastic; D002317:Cardiovascular Agents; D011929:Razoxane; D004317:Doxorubicin; D007501:Iron